Quantcast

Latest Metabasis Therapeutics Stories

2008-11-03 09:00:07

Metabasis Therapeutics (Nasdaq: MBRX) announced today that an oral presentation summarizing the results from the Company's Phase 2a clinical trial for MB07803 was given at the World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy), in Barcelona, Spain.

2008-09-24 09:00:49

Metabasis Therapeutics, a biopharmaceutical company, has initiated a clinical trial to evaluate higher doses of MB07803 in patients. MB07803 is Metabasis's second-generation FBPase inhibitor product candidate for the treatment of type 2 diabetes. The trial is expected to enroll at least 40 patients.

2008-07-29 18:00:20

Metabasis Therapeutics (Nasdaq: MBRX) announced today that an oral presentation summarizing the results from the Company's Phase 2a clinical trial for MB07803 will be given at the World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy), to be held in Barcelona, Spain, October 30 to November 2, 2008.

2008-06-16 12:01:05

Metabasis Therapeutics (Nasdaq: MBRX), announced today that Dr. Paul Laikind, president and chief executive officer, will present at the Jefferies 2nd Annual Healthcare Conference in New York, NY. Dr. Laikind is scheduled to present on Thursday, June 26 at 11:45 a.m.


Word of the Day
plim
  • To swell, as grain or wood with water.
The word 'plim' is probably a variant of the word 'plum'.
Related